LNP-Mediated Cell Transfection In Bioreactors Across Diverse Cell Therapy Workflows

Gene modification strategies for immune cells are evolving as researchers look beyond viral vectors and electroporation, which often introduce tradeoffs in cell viability, yield, and process complexity. Lipid nanoparticles (LNPs) are gaining attention for their lower cytotoxicity, reduced manufacturing demands, and compatibility with streamlined workflows. Interest is now shifting toward how these advantages translate at clinically relevant scales.

Recent data highlight LNP-mediated gene delivery across multiple immune cell types—including T cells, NK cells, and hematopoietic stem cells—within diverse bioreactor formats such as static, stirred-tank, rocking, and closed systems. These findings point to growing feasibility for integrating LNPs into scalable, controlled manufacturing environments.

Gain insight into how this approach could reshape ex vivo cell therapy processes and bridge the gap between preclinical promise and clinical implementation.